New drug manufacturing facility that is estimated to create more than 1,000 local jobs.

Company headquarters upgrades that are expected to create roughly 1,000 jobs across research and clinical manufacturing.

Part of a $70 billion U.S. investment plan.

Investment in U.S. capital projects, research and development to drive long-term growth and fortify America’s position as a global leader in drug innovation.

Amount includes previously announced projects in Rahway, NJ, Wilmington, DE, and Elkton, VA, which represent an estimated $7.5 billion commitment. The company also disclosed $3 billion in planned biologics and small molecule manufacturing sites and capabilities in the U.S., projected to create 800 additional jobs.

Broke ground on a project to enhance an existing site with a 400,000-square-foot Center of Excellence for pharmaceutical manufacturing. The facility will support small molecule manufacturing and testing and will potentially create more than 500 full-time roles as well as 8,000 construction jobs.

Part of a $70 billion U.S. investment plan.

A 15,000-square-meter factory that will be the Switzerland-based company’s first manufacturing facility in the United States. The facility will supply products solely for the U.S. market and is expected to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases.

A new manufacturing facility that is scheduled to increase output of various medicines, including cancer treatments, once operational within the next five to six years. Will create 3,600 direct and indirect jobs, including 3,000 tied to the project's construction phase.

Part of a larger, previously announced $50 billion investment.

Investing in U.S. operations over the next five years to upgrade and improve U.S. manufacturing sites.

Substantially increasing spending on U.S. R&D. Sanofi also announced plans to expand U.S.  manufacturing capacity, both through direct investments in Sanofi sites, as well as through partnerships with other domestic manufacturers, to help ensure the production of medicines in the U.S.